Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has commenced commercial supplies under its ₹825 crore Contract Development and Manufacturing Organization (CDMO) mandate, marking the transition of the program from validation and qualification to full-scale execution. The company confirmed that the first commercial dispatch, valued at approximately ₹50 crore, was completed during the first quarter of FY2026–27. The milestone represents the beginning of long-term supply execution under the agreement and reflects the successful completion of prior technical validation, manufacturing readiness, and supply chain alignment phases.
“This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships,” said Sanjay Suri, Managing Director of Morepen Laboratories Limited. “Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. With commercial supplies now underway, we are focused on scaling operations, expanding capacity and strengthening our CDMO platform for additional opportunities.”
Following the initial dispatch, Morepen expects to accelerate supply volumes under the mandate, with additional dispatches of approximately ₹225 crore anticipated in the second quarter of FY2026–27, subject to customer scheduling and regulatory and commercial requirements. The company is also expanding its manufacturing infrastructure to support the growing CDMO pipeline. Total reactor capacity is projected to reach approximately 600 kiloliters by the end of the second quarter, with further planned expansion to 800 kiloliters and 1,000 kiloliters in subsequent phases. The capacity augmentation is aimed at enabling higher-volume production and supporting multiple long-term manufacturing contracts.
Morepen stated that the commencement of commercial supplies reinforces its strategic focus on building a scalable CDMO platform and strengthening its position in global pharmaceutical manufacturing partnerships. The company is targeting deeper engagement with international customers across long-duration supply programs while enhancing operational efficiency and production capabilities. The CDMO mandate is part of Morepen’s broader effort to expand its manufacturing and export footprint across pharmaceutical active ingredients, formulations, diagnostics, and consumer healthcare products.
Morepen Laboratories Limited is a diversified pharmaceutical and healthcare company engaged in the development, manufacturing, and marketing of APIs, finished dosage formulations, diagnostic products, and consumer healthcare solutions. The company operates manufacturing facilities in India and serves domestic and international markets, with continued investments in research, regulatory compliance, and production scale-up to support long-term growth.
